mrna-vaccine

Documents about mrna-vaccine

• A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age#969196ClinicalTrials.gov
• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults#174932ClinicalTrials.gov
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older#314407ClinicalTrials.gov
• Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population#640437ClinicalTrials.gov
• Myocardial Injury After BNT162b2 mRNA COVID-19 Fourth Dose Vaccination Among Israeli Health Care Workers#979209ClinicalTrials.gov
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children#1009844ClinicalTrials.gov
• Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals#253540Europe PMC
• Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)#913738ClinicalTrials.gov
• Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years#123526ClinicalTrials.gov
• Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma#377265ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age#911744ClinicalTrials.gov
• A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age#918725ClinicalTrials.gov
• Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older#143659ClinicalTrials.gov
• Computational Design of an mRNA Vaccine Targeting LRP6 for Triple-Negative Breast Cancer Therapy.#159740NCBI PubMed Central
• Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors#201612ClinicalTrials.gov
• Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older#234478ClinicalTrials.gov
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age#369874ClinicalTrials.gov
• Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors#373590ClinicalTrials.gov
• Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma#435726ClinicalTrials.gov
• Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults#448315ClinicalTrials.gov
• Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates#455647PubMed Central
• The strategic importance of mRNA vaccine technologies in Africa for achieving public health independence#642622Europe PMC
• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age#857668ClinicalTrials.gov
• A Clinical Study of mRNA Vaccine (ABOR2014/IPM511) in Patients With Advanced Hepatocellular Carcinoma#195399ClinicalTrials.gov
• A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas#230484ClinicalTrials.gov
• Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Androgen Resistant Metastatic Prostate Cancer#268092ClinicalTrials.gov
• Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults#290839ClinicalTrials.gov
• A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults#307299ClinicalTrials.gov
• An mRNA-LNP vaccine expressing TP0435 provides protective immunity in rabbits against Treponema pallidum challenge.#308913NCBI PubMed Central
• A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil#810635ClinicalTrials.gov
• Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster#856634ClinicalTrials.gov
• Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination#435692ClinicalTrials.gov
• Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)#866914ClinicalTrials.gov
• Preliminary Immunogenicity Evaluation of an Immunoinformatics-Guided Multi-Epitope mRNA Vaccine Against Porcine Epidemic Diarrhea Virus.#232279NCBI PubMed Central
• Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants#463757ClinicalTrials.gov
• Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy#868570ClinicalTrials.gov
• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)#980993ClinicalTrials.gov
• A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection#471502ClinicalTrials.gov
• Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne#148579ClinicalTrials.gov
• Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells#190314Ora Oxford University Research
• A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults#245565ClinicalTrials.gov
• Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.#628574ClinicalTrials.gov
• Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients#1000755HAL (France)
• Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above#217114ClinicalTrials.gov
• Spleen-targeted neoantigen mRNA vaccine induces ISG15(+) CD8(+) T cell-mediated tertiary lymphoid structure formation in hepatocellular carcinoma.#223010NCBI PubMed Central
• Advances and Translational Challenges in Toxoplasma gondii Vaccine Development: From Antigen Discovery to mRNA and One Health Strategies.#232268NCBI PubMed Central
• Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants#261365ClinicalTrials.gov
• A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age#290843ClinicalTrials.gov
• Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above#307302ClinicalTrials.gov
• NOVEL RNA-BASED CANCER VACCINE FOR AML IMMUNOTHERAPY#330631ScholarBank@NUS